Compare AME & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AME | TAK |
|---|---|---|
| Founded | 1930 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5B | 43.3B |
| IPO Year | N/A | N/A |
| Metric | AME | TAK |
|---|---|---|
| Price | $196.97 | $14.31 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $213.00 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 3.2M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | 0.63% | ★ 1.91% |
| EPS Growth | ★ 10.46 | N/A |
| EPS | ★ 6.34 | 0.14 |
| Revenue | $7,164,270,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $6.18 | $0.01 |
| Revenue Next Year | $7.53 | $0.49 |
| P/E Ratio | ★ $30.85 | $103.78 |
| Revenue Growth | ★ 3.67 | N/A |
| 52 Week Low | $145.02 | $12.80 |
| 52 Week High | $204.15 | $15.69 |
| Indicator | AME | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 54.45 |
| Support Level | $188.47 | $14.38 |
| Resistance Level | $198.53 | $14.54 |
| Average True Range (ATR) | 3.44 | 0.15 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 69.36 | 62.16 |
Founded in 1930 and transformed over the decades through the acquisition of dozens of esteemed brands, Ametek owns a collection of over 40 autonomous industrial businesses operating within the research, aerospace, energy, medical, and manufacturing industries. Ametek segments its business into two operating groups: the electronic instruments group and the electromechanical group. The EIG sells a broad portfolio of analytical, test, and measurement instruments, while the EMG sells highly engineered components, interconnects, and specialty metals. The company emphasizes product differentiation and market leadership in the niche markets where it operates.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.